Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction

Konstantinou, Dimitrios; Chatzizisis, Yiannis S.; Giannoglou, George D.

doi:10.1016/j.pharmthera.2013.05.012

Cited by 15 publications

(15 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatments shown to be beneficial in phase II studies, await validation in phase III studies. Other treatments appear promising in preclinical studies but await translation [107,108]. Device therapies, that have revolutionized the treatment of HFrEF with millions of patients receiving implantable defibrillators, biventricular pacemakers, left ventricular assist devices, or total artificial heart to improve survival, are not available to patients with HFpEF primarily due to lack of clinical studies regarding the specific device, further limiting the therapeutic approach to HFpEF.…”

Section: Therapeutic Approach To Hfpefmentioning

confidence: 99%

Heart failure with preserved ejection fraction: Refocusing on diastole

Abbate

Arena

Abouzaki

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Therapeutic Approach To Hfpefmentioning

confidence: 99%

Heart failure with preserved ejection fraction: Refocusing on diastole

Abbate

Arena

Abouzaki

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…Prevention of the formation of new AGEs with exercise and breakdown of already formed AGEs with ALT-711 may represent a therapeutic strategy for age-related ventricular and vascular stiffness (223). Other treatments appear promising in preclinical studies but await translation (7,130).…”

Section: Sild Ena Fil (Re La X Stu Dy)mentioning

confidence: 99%

Myocardial reverse remodeling: how far can we rewind?

Gonçalves-Rodrigues

Leite‐Moreira

Falcão-Pires

2016

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

Heart failure (HF) is a systemic disease that can be divided into HF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). HFpEF accounts for over 50% of all HF patients and is typically associated with high prevalence of several comorbidities, including hypertension, diabetes mellitus, pulmonary hypertension, obesity, and atrial fibrillation. Myocardial remodeling occurs both in HFrEF and HFpEF and it involves changes in cardiac structure, myocardial composition, and myocyte deformation and multiple biochemical and molecular alterations that impact heart function and its reserve capacity. Understanding the features of myocardial remodeling has become a major objective for limiting or reversing its progression, the latter known as reverse remodeling (RR). Research on HFrEF RR process is broader and has delivered effective therapeutic strategies, which have been employed for some decades. However, the RR process in HFpEF is less clear partly due to the lack of information on HFpEF pathophysiology and to the long list of failed standard HF therapeutics strategies in these patient's outcomes. Nevertheless, new proteins, protein-protein interactions, and signaling pathways are being explored as potential new targets for HFpEF remodeling and RR. Here, we review recent translational and clinical research in HFpEF myocardial remodeling to provide an overview on the most important features of RR, comparing HFpEF with HFrEF conditions.

show abstract

“…A recently published pathophysiology-based novel pharmacotherapy for these patients considers spironolactone, aliskiren, and neprilisyn as therapeutic options for HFPEF because of their anti-hypertrophic and anti-fibrotic effects [41]. Combined ventricular and vascular stiffening involving both the systemic and pulmonary circulations, plays a role in the pathophysiology of HFpEF [42, 43].…”

Section: Discussionmentioning

confidence: 99%

Effect of Ivabradine on Endothelial Function in Diastolic and Right Heart Failure Patients

Orea-Tejeda

Balderas-Muñoz

Castillo-Martı́nez

et al. 2013

Cardiology Research and Practice

View full text Add to dashboard Cite

Background. Ivabradine is an If ion current inhibitor that has proved to reduce mortality in patients with systolic heart failure by slowing heart rate without decreasing myocardial contractility. Photoplethysmography is a simple, low-cost optical technique that can evaluate vascular function and detect changes in blood flow, pulse, and swelling of tissular microvascular space. Objective. To evaluate the effect of ivabradine on endothelial function by photoplethysmography in diastolic and right heart failure patients. Methodology. 15 patients were included (mean age of 78.1 ± 9.2 years) with optimally treated diastolic and right heart failure. They underwent photoplethysmography before and after induced ischemia to evaluate the wave blood flow on the finger, using the maximum amplitude time/total time (MAT/TT) index. Two measurements were made before and after oral Ivabradine (mean 12.5 mg a day during 6 months of followup). Results. In the study group, the MAT/TT index was 29.1 ± 2.2 versus 24.3 ± 3.2 (P = 0.05) in basal recording and 30.4 ± 2.1 versus 23.3 ± 2.9 (P = 0.002), before versus after ischemia and before versus after Ivabradine intervention, respectively. Conclusions. Ivabradine administration improves endothelial function (shear stress) in diastolic and right heart failure patients.

show abstract

Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction

Cited by 15 publications

References 123 publications

Heart failure with preserved ejection fraction: Refocusing on diastole

Heart failure with preserved ejection fraction: Refocusing on diastole

Myocardial reverse remodeling: how far can we rewind?

Effect of Ivabradine on Endothelial Function in Diastolic and Right Heart Failure Patients

Contact Info

Product

Resources

About